OBI Pharma announces COVID-19 vaccine clinical trials to start in 2022

Taiwan-based biotech firm OBI Pharma Inc. announced Tuesday that the COVID-19 vaccine it developed called BCVax will enter phase 1 & 2 clinical trials in the second half of this year.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)